French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Thursday that it has received European Commission approval for VaxRabeo, its next-generation rabies vaccine, for pre-exposure and post-exposure prophylaxis in patients of all ages.
This approval marks the vaccine's first marketing authorisation and follows a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use in September 2026.
Manufactured using Vero-cell technology, VaxRabeo is designed to reduce the risk of allergic reactions and offers improved thermostability and a longer shelf life compared with Sanofi's existing rabies vaccines.
The approval is supported by clinical studies comparing VaxRabeo with Sanofi's existing vaccines, Verorab and Imovax Rabies, across different age groups and recommended vaccination schedules. Results showed comparable protective antibody levels in pre-exposure settings, similar immunogenicity in post-exposure treatment and strong booster responses, with no significant safety concerns.
Rabies remains a major global public health challenge, affecting 150 countries and causing approximately 59,000 deaths annually, according to World Health Organization estimates. Although the disease is preventable through vaccination, it is almost always fatal once symptoms develop.
Apotex launches generic version of INLYTA in US market
Genentech secures first FDA approval for primary membranous nephropathy treatment
ViiV Healthcare receives positive EU recommendation for expanded paediatric HIV treatments
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
Sunnyside adds GLP-1 options to its medication program for Alcohol Use Disorder
Traws Pharma reports final Phase 2a COVID-19 data and advances influenza programme
Shanton Pharma's SAP-001 receives EMA and FDA paediatric study waivers in hyperuricaemia
Ascletis announces submission of US IND application for oral obesity combination therapy
bioMérieux secures FDA clearance and IVDR CE marking for VITEK PRO diagnostic platform
Compass Pathways completes FDA application for COMP360 in treatment-resistant depression
bioMérieux secures FDA clearance for updated gastrointestinal diagnostic panels